The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

It also develops and manufactures vaccines. Pfizer collaborated ... first COVID-19 vaccine to gain full approval for use in the U.S. More recently, it received FDA approval in February 2025 ...

serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A and RSV-B subgroups are clustered in a key antigenic site, a target for potent neutralizing antibodies.

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved ... an application to the ...